|
Home | Medical-Newswire.Com:
|
 (EMAILWIRE.COM, January 19, 2012 ) Montreal, Canada -- By Sai Rosen
Since the late 1990Â’s, the world has been told that using our own stem cells would someday lead to cures and treatments for unmet medical needs. ALS, AlzheimerÂ’s, ParkinsonÂ’s, macular degeneration (AMD) and acute myocardial infarction (AMI) were on the short list of proposed therapeutic concentrations of research. Unfortunately in the excitement of an upcoming paradigm shift in healthcare, the world failed to realize that the translation of regenerative medicine into humans and ultimately to reach commercialization is a long, winding and arduous journey. The credit crisis and ongoing venture capital crisis in the area of life science has further delayed research and translation. Most notably, Geron Corporation (Nasdaq:GERN) decided to halt its FDA clinical trial for spinal cord injuries.
InvestorStemCell.com strongly believes that validation in regenerative medicine using human embryonic stem cells, hematopoietic stem cells, and bone marrow stromal stem cells, also called mesenchymal stem cells, is likely in 2012. So what is validation? Validation can be of many forms. Is it safe? Will it ease suffering? Does it work as designed? This is efficacy, the 8 letter word that every company wants a peer reviewed journal to declare about its therapy.
The below publicly traded companies are nearing proof of concept and may achieve validation in 2012. They are off the radar, trading at near all-time lows, yet their science is on the cusp of validation. Many of the companies are at the halfway point in the 15-20 year cycle of research and development with the ultimate goal of commercialization of drug(s). If proof of concept is achieved, the investment capital of mainstream, institutional investors and retail investors will rush in and ultimately lift the company firmly out of the valley of death for good. If you are risk adverse I would advise looking elswhere for an investment. Clinical stage companies can provide excellent return on investment but are not for the faint of heart. If you can stomache volatility and risk for the unproven science of regenerative medicine and thus balance the reward then take a long look.
• Aastrom Biosciences (NASDAQ:ASTM) Phase 3 Clinical Trial Critical Limb Ischemia
Trading at $1.91; near all-time lows
* Advanced Cell Technology (OTCBB:ACTC) Phase 1/2 U.S.-EU Trial for AMD and SMD
Trading at $0.15; near all-time lows
* Athersys, Inc.(NASDAQ:ATHX) Launching three Phase 2 trials in AMI, IBD,&stroke.
Trading at $2.00
• Brainstorm Cell Therapeutics Inc (OTCBB:BCLI) Phase I/II for ALS in Israel
Trading at $0.26
• BioTime, Inc. (AMEX-BTX) Has 7 subsidiaries,positioned for explosive growth
Trading at $5.28
• Cytori Therapeutics (NASDAQ: CYTX) Advanced trial in EU for AMI-Cardiovascular
Trading at $2.73; near all-time lows
• Neuralstem, Inc.(NYSEAMEX:CUR) Phase 1 for ALS in US. FDA cervical region ok.
Trading at $1.08; near all-time lows
American CryoStem (OTCBB:CRYO) has just been added to the Investor Stem Cell watch list for 2012. The Company has a proprietary storage platform for adipose tissue. The emerging market of Bio-Insurance makes CRYO a likely growth opportunity for 2012.
Begin your research at Investor Stem Cell: www.InvestorStemCell.com the worldÂ’s only on-line message forum dedicated to stem cell investors.
• Disclaimer Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in a newsletter, website etc. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
About Investor Stem Cell
Investor Stem Cell is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements in the regenerative medicine sector.
Press Release Courtesy of Online PR Media: http://bit.ly/wPcSK6
Stem Cell Media, LLC
Sai Rosen
866-754-0457
icell@investorstemcell.com 
Source: EmailWire.com
|
|
|
|
